249 related articles for article (PubMed ID: 32429551)
1. Assessment and Management of Platinum-Related Ototoxicity in Children Treated for Cancer.
Romano A; Capozza MA; Mastrangelo S; Maurizi P; Triarico S; Rolesi R; Attinà G; Fetoni AR; Ruggiero A
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429551
[TBL] [Abstract][Full Text] [Related]
2. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
3. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
4. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
5. Long-term auditory follow-up in the management of pediatric platinum-induced ototoxicity.
Fetoni AR; Brigato F; De Corso E; Lucidi D; Sergi B; Scarano E; Galli J; Ruggiero A
Eur Arch Otorhinolaryngol; 2022 Oct; 279(10):4677-4686. PubMed ID: 35024956
[TBL] [Abstract][Full Text] [Related]
6. Platinum-induced ototoxicity in pediatric cancer survivors: GSTP1 c.313A>G variant association.
Sherief LM; Rifky E; Attia M; Ahmed R; Kamal NM; Oshi MAM; Hanna D
Medicine (Baltimore); 2022 Nov; 101(45):e31627. PubMed ID: 36397425
[TBL] [Abstract][Full Text] [Related]
7. Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents.
Gersten BK; Fitzgerald TS; Fernandez KA; Cunningham LL
J Assoc Res Otolaryngol; 2020 Aug; 21(4):303-321. PubMed ID: 32583132
[TBL] [Abstract][Full Text] [Related]
8. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; (8):CD010885. PubMed ID: 27498707
[TBL] [Abstract][Full Text] [Related]
9. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jun; (6):CD010885. PubMed ID: 24968257
[TBL] [Abstract][Full Text] [Related]
10. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients.
Waissbluth S; Del Valle Á; Chuang A; Becker A
Int J Pediatr Otorhinolaryngol; 2018 Aug; 111():174-179. PubMed ID: 29958605
[TBL] [Abstract][Full Text] [Related]
11. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
[TBL] [Abstract][Full Text] [Related]
12. The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer.
Vermorken JB
Int J Gynecol Cancer; 2001; 11 Suppl 1():21-30. PubMed ID: 11488999
[TBL] [Abstract][Full Text] [Related]
13. Audiological Monitoring in Children Treated with Platinum Chemotherapy.
Fetoni AR; Ruggiero A; Lucidi D; De Corso E; Sergi B; Conti G; Paludetti G
Audiol Neurootol; 2016; 21(4):203-211. PubMed ID: 27286730
[TBL] [Abstract][Full Text] [Related]
14. Potential use of n-3 PUFAs to prevent oxidative stress-derived ototoxicity caused by platinum-based chemotherapy.
Cortés Fuentes IA; Burotto M; Retamal MA; Frelinghuysen M; Caglevic C; Gormaz JG
Free Radic Biol Med; 2020 Nov; 160():263-276. PubMed ID: 32827639
[TBL] [Abstract][Full Text] [Related]
15. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
[TBL] [Abstract][Full Text] [Related]
16. Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria.
Waissbluth S; Peleva E; Daniel SJ
Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1187-1196. PubMed ID: 27245751
[TBL] [Abstract][Full Text] [Related]
17. Protection and spontaneous recovery from cisplatin-induced hearing loss.
Smoorenburg GF; De Groot JC; Hamers FP; Klis SF
Ann N Y Acad Sci; 1999 Nov; 884():192-210. PubMed ID: 10842594
[TBL] [Abstract][Full Text] [Related]
18. Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9).
Schweitzer VG; Rarey KE; Dolan DF; Abrams G; Litterst CJ; Sheridan C
Otolaryngol Head Neck Surg; 1986 Apr; 94(4):458-70. PubMed ID: 3086808
[TBL] [Abstract][Full Text] [Related]
19. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale.
Brock PR; Knight KR; Freyer DR; Campbell KC; Steyger PS; Blakley BW; Rassekh SR; Chang KW; Fligor BJ; Rajput K; Sullivan M; Neuwelt EA
J Clin Oncol; 2012 Jul; 30(19):2408-17. PubMed ID: 22547603
[TBL] [Abstract][Full Text] [Related]
20. Understanding platinum-induced ototoxicity.
Langer T; am Zehnhoff-Dinnesen A; Radtke S; Meitert J; Zolk O
Trends Pharmacol Sci; 2013 Aug; 34(8):458-69. PubMed ID: 23769626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
